Antibiotic Recommendations for Infected Pulmonary Tuberculosis with Bronchiectasis

Antibiotic Selection Based on Pathogen

The British Thoracic Society guidelines recommend targeted antibiotic therapy based on pathogen identification, with specific regimens for Pseudomonas aeruginosa and other common pathogens, for patients with infected pulmonary tuberculosis and bronchiectasis 1, 2
For patients with chronic Pseudomonas aeruginosa infection who experience three or more exacerbations per year, first-line treatment is inhaled colistin 1, 3
Inhaled gentamicin is a second-line alternative for patients with Pseudomonas aeruginosa infection who cannot tolerate colistin 2, 3
Azithromycin or erythromycin can be used as an alternative oral option for patients who cannot tolerate inhaled antibiotics 2
Combination therapy with azithromycin or erythromycin and inhaled antibiotics can be considered for patients with high exacerbation frequency 1

For Streptococcus pneumoniae infections, first-line treatment is amoxicillin 500 mg three times daily for 14 days, with doxycycline 100 mg twice daily for 14 days as an alternative 4
For Haemophilus influenzae infections, beta-lactamase negative patients can be treated with amoxicillin 500 mg three times daily for 14 days, while beta-lactamase positive patients require amoxicillin with clavulanic acid 625 mg three times daily for 14 days 4

For new Pseudomonas aeruginosa growth, first-line eradication therapy is ciprofloxacin 500-750 mg twice daily for 2 weeks, with IV anti-pseudomonal beta-lactam ± IV aminoglycoside for 2 weeks as a second-line option 4
Eradication therapy is recommended for new MRSA growth, especially due to infection control concerns 5

For patients with ≥3 exacerbations/year, a stepwise approach is recommended, including optimization of airway clearance, use of long-term inhaled anti-pseudomonal antibiotic or long-term macrolide, and consideration of targeted antibiotics or long-term macrolides 1

Antimicrobial stewardship is essential to prevent resistance development 2
Long-term macrolides should not be started without ensuring no active NTM infection with at least one negative respiratory NTM culture 2
Aminoglycosides should be used with caution in patients with significant hearing loss or balance issues, and avoided in patients with creatinine clearance <30ml/min or concomitant nephrotoxic medications 2
Patients on long-term antibiotics should be monitored every 6 months to assess efficacy, toxicity, and continuing need 2, 3
Regular monitoring of sputum culture and sensitivity is recommended, although in vitro resistance may not affect clinical efficacy 2